

Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

Giuliano Palumbo¹

¹ Department of thoracic oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy

Potential competing interests: No potential competing interests to declare.

I found your work interesting, and I'm in line with your conclusions; I think the most interesting part is your focus on the censoring problem of the Code-Break, which has been already reported but never addressed so well.

Just some minor issues:

- When talking about "left censoring is evident": could you make it clearer for the reader?
- "In conclusion, according to this analysis, Amgen, the FDA, and The Lancet may jeopardize lung cancer patients' prognosis."

I suggest rephrasing the sentence with something like "In conclusion, according to this analysis, Amgen, the FDA, and The Lancet should reconsider the results of the Codebreak 201 trial and the decisions derived from those results, in order not to jeopardize lung cancer patients' prognosis."

- I suggest also citing at least the work made by Olivier, Haslam, and Prasad <https://pmc.ncbi.nlm.nih.gov/articles/PMC9803768/> which goes in the same direction as yours.

Congratulations on your work, regards.